Compare FCCO & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCCO | PLYX |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.5M | 271.8M |
| IPO Year | 2012 | N/A |
| Metric | FCCO | PLYX |
|---|---|---|
| Price | $32.58 | $2.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 135.5K | ★ 144.0K |
| Earning Date | 04-22-2026 | 05-22-2026 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | ★ 36.46 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $922,000.00 | N/A |
| Revenue This Year | $30.67 | N/A |
| Revenue Next Year | $5.87 | N/A |
| P/E Ratio | $56.15 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.00 | $2.01 |
| 52 Week High | $34.01 | $9.18 |
| Indicator | FCCO | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 60.87 | 43.62 |
| Support Level | $29.26 | $2.10 |
| Resistance Level | $33.03 | $3.41 |
| Average True Range (ATR) | 0.97 | 0.22 |
| MACD | 0.09 | 0.09 |
| Stochastic Oscillator | 58.63 | 78.05 |
First Community Corp is a bank holding company. Along with its subsidiaries, it provides various banking products and services for professionals and small and medium-sized businesses, including consumer and commercial banking, mortgage, brokerage and investment, online banking, and insurance services. The company offers checking, savings, money market, individual retirement, and certificates of deposit accounts, and its lending lines include consumer loans, real estate loans, home improvement loans, home loans, flex loans, construction loans, agricultural loans, and others. The company's reportable segments are: Commercial and Retail Banking, which derives maximum revenue; Mortgage Banking; Investment Advisory and Non-Deposit; and Corporate.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.